Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S. Farag, Clara D. Bloomfield, Andrew J. Carroll et al.|Blood|2006Cited by 332
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B StudySherif S. Farag, Clara D. Bloomfield, Amy S. Ruppert et al.|Journal of Clinical Oncology|2004Cited by 138